Last CNY26.17 CNY
Change Today +0.23 / 0.89%
Volume 875.8K
As of 3:05 AM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for tibet rhodiola pharm-a (600211)

Year over year, Tibet Rhodiola Pharmaceutical Holding Company has seen their bottom line shrink from CNY30.5M CNY to CNY27.2M CNY despite an increase in revenues from CNY1.2B CNY to CNY1.4B CNY. An increase in the percentage of sales devoted to SGA costs from 17.44% to 17.77% was a key component in the falling bottom line in the face of rising revenues.
View Income Statement In U.S. Dollar
Currency in
Millions of Chinese Renminbi (Yuan)s
As of:Dec 31
2010
Restated
CNY
Dec 31
2011
Restated
CNY
Dec 31
2012
Restated
CNY
Dec 31
2013
CNY
4 Year
Trend
Revenues1,099.91,068.81,211.01,392.3
Other Revenues10.910.210.49.9
TOTAL REVENUES1,110.71,079.01,221.41,402.2
Cost of Goods Sold920.4887.7982.21,124.1
GROSS PROFIT190.3191.4239.2278.1
Selling General & Admin Expenses, Total167.1174.8211.2247.4
Other Operating Expenses-9.6-8.0-11.1-9.7
OTHER OPERATING EXPENSES, TOTAL157.5166.8200.1237.6
OPERATING INCOME32.824.639.140.5
Interest Expense-6.0-5.7-10.5-11.2
Interest and Investment Income3.42.08.76.6
NET INTEREST EXPENSE-2.6-3.8-1.8-4.6
Currency Exchange Gains (Loss)0.00.00.00.0
Other Non-Operating Income (Expenses)0.11.7-2.1-1.8
EBT, EXCLUDING UNUSUAL ITEMS30.322.535.234.1
Gain (Loss) on Sale of Assets0.00.00.00.0
Other Unusual Items, Total-0.41.0-3.2-4.0
Legal Settlements-----0.70.0
Other Unusual Items-0.41.03.73.6
EBT, INCLUDING UNUSUAL ITEMS30.023.432.030.1
Income Tax Expense5.82.31.56.1
Minority Interest in Earnings-0.6-0.60.03.2
Earnings from Continuing Operations24.221.130.524.0
NET INCOME23.620.530.527.2
NET INCOME TO COMMON INCLUDING EXTRA ITEMS23.620.530.527.2
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS23.620.530.527.2
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600211:CH CNY26.17 CNY +0.23

600211 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600211.
View Industry Companies
 

Industry Analysis

600211

Industry Average

Valuation 600211 Industry Range
Price/Earnings 100.0x
Price/Sales 2.6x
Price/Book 9.7x
Price/Cash Flow 118.6x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIBET RHODIOLA PHARM-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.